Title |
The biology and management of non-small cell lung cancer
|
---|---|
Published in |
Nature, January 2018
|
DOI | 10.1038/nature25183 |
Pubmed ID | |
Authors |
Roy S. Herbst, Daniel Morgensztern, Chris Boshoff |
Abstract |
Important advancements in the treatment of non-small cell lung cancer (NSCLC) have been achieved over the past two decades, increasing our understanding of the disease biology and mechanisms of tumour progression, and advancing early detection and multimodal care. The use of small molecule tyrosine kinase inhibitors and immunotherapy has led to unprecedented survival benefits in selected patients. However, the overall cure and survival rates for NSCLC remain low, particularly in metastatic disease. Therefore, continued research into new drugs and combination therapies is required to expand the clinical benefit to a broader patient population and to improve outcomes in NSCLC. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 44 | 26% |
United Kingdom | 18 | 11% |
Spain | 11 | 6% |
France | 9 | 5% |
Canada | 5 | 3% |
Ecuador | 2 | 1% |
Saudi Arabia | 2 | 1% |
India | 2 | 1% |
Japan | 2 | 1% |
Other | 15 | 9% |
Unknown | 61 | 36% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 99 | 58% |
Scientists | 48 | 28% |
Practitioners (doctors, other healthcare professionals) | 18 | 11% |
Science communicators (journalists, bloggers, editors) | 6 | 4% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 2099 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 258 | 12% |
Student > Bachelor | 247 | 12% |
Student > Master | 230 | 11% |
Researcher | 210 | 10% |
Other | 96 | 5% |
Other | 280 | 13% |
Unknown | 778 | 37% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 469 | 22% |
Medicine and Dentistry | 287 | 14% |
Agricultural and Biological Sciences | 126 | 6% |
Pharmacology, Toxicology and Pharmaceutical Science | 100 | 5% |
Immunology and Microbiology | 56 | 3% |
Other | 218 | 10% |
Unknown | 843 | 40% |